Nasdaq-listed biotech firm Sonnet BioTherapeutics announced Monday a $888 million merger agreement with Rorschach I LLC, an ...

Sonnet BioTherapeutics enters into an agreement to transform into the largest U.S.-based publicly listed company to hold HYPE ...

Sonnet BioTherapeutics (NASDAQ:SONN) saw its stock soar by 290% after announcing an $888 million business combination that will pivot the company into a cryptocurrency treasury focused on HYPE tokens.

Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasuryPRINCETON, N.J., July 14, 2025 ( ...

Hyperliquid (HYPE) trades near $48 on Monday following Sonnet BioTherapeutics' (SONN) announcement that it has entered a ...

Sonnet to merge with crypto-backed firm, forming Hyperliquid Strategies with $888 million in assets, plus HYPE blockchain ...

Sonnet BioTherapeutics will transform into a new entity called HyperLiquid Strategies at the agreement's close. The new company is expected to hold 12.6 million HYPE tokens and gross cash invested of ...

Sonnet BioTherapeutics pivots to crypto with $888M deal, forming Hyperliquid Strategies Inc. to hold 12.6M HYPE tokens.

HYPE rallies toward $50 after Sonnet BioTherapeutics combines with Rorschach to launch a $583 million Hyperliquid token ...

Sonnet BioTherapeutics Holdings Inc has a consensus price target of $10.18 based on the ratings of 4 analysts. The high is $20 issued by Chardan Capital on April 7, 2025.The low is $6.7 issued by ...

Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and ...